(Globes) Gali Weinreb - The U.S. government's Biomedical Advanced R&D Authority (BARDA) will inject $32 million more into developing the Israeli company MediWound's burns treatments, after previously investing $100 million. MediWound's products are designed for the removal of dead tissue in burns and hard-to-heal wounds. The product is produced from the pineapple plant and removes 100% of the dead tissue with no harm to healthy tissue. The small size of the market has hampered funding for development. Under the revised agreement, BARDA is paying for all the trials necessary in order to obtain approval of the product in the U.S., plus the trial currently being conducted for treatment of burns in children. MediWound founder Prof. Lior Rosenberg, a former chairman of the International Society for Burn Injuries disaster committee, said, "The current management of pediatric burns requires intensive medical therapy and typically several traumatic surgical procedures....MediWound is aiming to replace the traumatic conventional treatments for burns."
2017-08-04 00:00:00Full ArticleBACK Visit the Daily Alert Archive